HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates With Disease Activity, Autoantibodies, and NETosis.

AbstractBackground:
Interleukin 40 (IL-40) is a newly identified B cell-associated cytokine implicated in humoral immune responses and B cell homeostasis. As B cells play a pivotal role in autoimmunity, we investigated the function of IL-40 in rheumatoid arthritis (RA).
Methods:
IL-40 expression was determined in the synovial tissue from RA and osteoarthritis (OA) patients. IL-40 was analysed in the serum/synovial fluid of patients with RA (n=50), systemic lupus erythematosus (SLE, n=69), OA (n=44), and healthy controls (HC, n=50). We assessed the changes of IL-40 levels in RA patients following the B cell depletion by rituximab (n=29) or after the TNF inhibition by adalimumab (n=25). We examined the relationship between IL-40, disease activity, autoantibodies, cytokines, and NETosis markers. Effect of IL-40 on synovial fibroblasts was determined.
Results:
IL-40 was overexpressed in RA synovial tissue, particularly by synovial lining and infiltrating immune cells. The levels of IL-40 were up-regulated in the synovial fluid of RA versus OA patients (p<0.0001). Similarly, IL-40 was increased in the serum of RA patients compared to HC, OA, or SLE (p<0.0001 for all) and decreased after 16 and 24 weeks (p<0.01 and p<0.01) following rituximab treatment. No significant effect of adalimumab on IL-40 was observed. IL-40 levels in RA patients correlated with rheumatoid factor-IgM and anti-cyclic citrullinated peptides (anti-CCP) in the serum (p<0.0001 and p<0.01), as well as in the synovial fluid (p<0.0001 and p<0.001). Synovial fluid IL-40 was also associated with disease activity score DAS28 (p<0.05), synovial fluid leukocyte count (p<0.01), neutrophil attractants IL-8 (p<0.01), MIP-1α (p<0.01), and markers of neutrophil extracellular traps externalization (NETosis) such as proteinase 3 (p<0.0001) and neutrophil elastase (p<0.0001). Synovial fibroblasts exposed to IL-40 increased the secretion of IL-8 (p<0.01), MCP-1 (p<0.05), and MMP-13 (p<0.01) compared to the unstimulated cells.
Conclusions:
We show the up-regulation of IL-40 in RA and its decrease following B cell depleting therapy. The association of IL-40 with autoantibodies, chemokines, and markers of NETosis may imply its potential involvement in RA development. Moreover, IL-40 up-regulates the secretion of chemokines and MMP-13 in synovial fibroblasts, indicating its role in the regulation of inflammation and tissue destruction in RA.
AuthorsAdela Navrátilová, Lucie Andrés Cerezo, Hana Hulejová, Viktor Bečvář, Michal Tomčík, Martin Komarc, David Veigl, Dana Tegzová, Jakub Závada, Marta Olejárová, Karel Pavelka, Jiří Vencovský, Ladislav Šenolt
JournalFrontiers in immunology (Front Immunol) Vol. 12 Pg. 745523 ( 2021) ISSN: 1664-3224 [Electronic] Switzerland
PMID34745117 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2021 Navrátilová, Andrés Cerezo, Hulejová, Bečvář, Tomčík, Komarc, Veigl, Tegzová, Závada, Olejárová, Pavelka, Vencovský and Šenolt.
Chemical References
  • Antirheumatic Agents
  • Autoantibodies
  • Biomarkers
  • C17orf99 protein, human
  • Cytokines
  • Interleukins
  • Tumor Necrosis Factor-alpha
  • Rituximab
  • Matrix Metalloproteinase 13
  • Adalimumab
Topics
  • Adalimumab (therapeutic use)
  • Adult
  • Aged
  • Antirheumatic Agents (pharmacology, therapeutic use)
  • Arthritis, Rheumatoid (immunology, therapy)
  • Autoantibodies (blood)
  • B-Lymphocytes (drug effects, immunology)
  • Biomarkers
  • Cells, Cultured
  • Cohort Studies
  • Cytokines (analysis)
  • Extracellular Traps (immunology)
  • Female
  • Fibroblasts
  • Gene Expression Regulation (drug effects)
  • Humans
  • Interleukins (metabolism)
  • Lupus Erythematosus, Systemic (immunology, metabolism)
  • Lymphocyte Depletion
  • Male
  • Matrix Metalloproteinase 13 (analysis)
  • Middle Aged
  • Osteoarthritis, Knee (immunology, metabolism)
  • Rituximab (pharmacology, therapeutic use)
  • Synovial Fluid (chemistry, immunology)
  • Synovial Membrane (chemistry, immunology)
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: